We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Two New Diagnostic Tests Can Differentiate Between COVID-19 Variants and Multiple Viruses with Rapid Turnaround Times

By LabMedica International staff writers
Posted on 24 Feb 2021
Print article
Illustration
Illustration
Two new tests can differentiate between COVID-19 variants and multiple viruses with rapid turnaround times.

Researchers at University of Minnesota Medical School (Minneapolis, MN, USA) have developed two new rapid diagnostic tests for COVID-19 - one to detect COVID-19 variants and one to help differentiate with other illnesses that have COVID-19-like symptoms.

The first test is a rapid diagnostic test that can differentiate between COVID-19 variants. This test can be performed without specialized expertise or equipment. It uses technology similar to at-home pregnancy testing and produces results in about an hour. The second, more sensitive test allows researchers to analyze the same sample simultaneously for COVID-19 (SARS-CoV-2), Influenza A and B and respiratory syncytial virus by measuring fluorescence. These viruses manifest with similar symptoms, so being able to detect and differentiate them adds a new diagnostic tool to slow the spread of COVID-19. This test also takes about an hour and could be easily scaled so many more tests can be performed. The necessary equipment is present in most diagnostics laboratories and many research laboratories.

The technology for both tests uses the cutting-edge CRISPR/Cas9 system. Using commercial reagents, they describe a Cas-9-based methodology for nucleic acid detection using lateral flow assays and fluorescence signal generation. The researchers are now seeking to enhance sensitivity and real-world application of the first test in support of rapidly detecting and identifying COVID-19 variants. In order to provide access to their new testing technology for healthcare providers and the public, the researchers are currently exploring ways to scale up and license their new diagnostics.

“The approval of the SARS-CoV-2 vaccine is highly promising, but the time between first doses and population immunity may be months,” said Mark J. Osborn, PhD, assistant professor of Pediatrics at the University of Minnesota Medical School and first author of this paper. “This testing platform can help bridge the gap between immunization and immunity.”

Related Links:
University of Minnesota Medical School

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.